Thompson IM - Search Results

1

Screening for prostate cancer: opportunities and challenges.

Thompson IM, Bermejo C, Hernandez J, Basler JA, Canby-Hagino E. Thompson IM, et al. Surg Oncol Clin N Am. 2005 Oct;14(4):747-60. doi: 10.1016/j.soc.2005.07.001. Surg Oncol Clin N Am. 2005. PMID: 16226689 Review.

2

Impact of previous local treatment for prostate cancer on subsequent metastatic disease.

Thompson IM, Tangen C, Basler J, Crawford ED. Thompson IM, et al. J Urol. 2002 Sep;168(3):1008-12. doi: 10.1016/S0022-5347(05)64562-4. J Urol. 2002. PMID: 12187210 Clinical Trial.

3

Ventral bladder hernia following tubal ligation.

Peña AA, Bermejo CE, Thompson IM Jr. Peña AA, et al. Among authors: thompson im jr. J Urol. 2002 Oct;168(4 Pt 1):1502. doi: 10.1016/S0022-5347(05)64491-6. J Urol. 2002. PMID: 12352435 No abstract available.

4

Challenges and opportunities to the design and implementation of chemoprevention trials for prostate cancer.

Thompson IM, Basler JA, Leach R, Troyer D, Klein E, Brawley O. Thompson IM, et al. Urol Oncol. 2003 Jan-Feb;21(1):73-8. doi: 10.1016/s1078-1439(02)00302-2. Urol Oncol. 2003. PMID: 12684131 Review.

5

Management of high-risk localized prostate cancer: the integration of local and systemic therapy approaches.

Syed S, Petrylak DP, Thompson IM. Syed S, et al. Among authors: thompson im. Urol Oncol. 2003 May-Jun;21(3):235-43. doi: 10.1016/s1078-1439(03)00033-4. Urol Oncol. 2003. PMID: 12810212 Review.

6

The influence of finasteride on the development of prostate cancer.

Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. Thompson IM, et al. N Engl J Med. 2003 Jul 17;349(3):215-24. doi: 10.1056/NEJMoa030660. Epub 2003 Jun 24. N Engl J Med. 2003. PMID: 12824459 Free article. Clinical Trial.

7

Prostate cancer prevention: what do we know now and when will we know more?

Thompson IM, Basler J, Hensley D, von Merveldt D, Jenkins CA, Higgins B, Leach R, Troyer D, Pollock B. Thompson IM, et al. Clin Prostate Cancer. 2003 Mar;1(4):215-20. doi: 10.3816/cgc.2003.n.002. Clin Prostate Cancer. 2003. PMID: 15040879 Review.

8

What's new in the field of prostate cancer chemoprevention?

Mahal K, Hernandez J, Basler JW, Thompson IM. Mahal K, et al. Among authors: thompson im. Curr Oncol Rep. 2004 May;6(3):237-42. doi: 10.1007/s11912-004-0055-9. Curr Oncol Rep. 2004. PMID: 15066236 Review.

9

The potential role of cyclooxygenase-2 inhibitors and 5alpha-reductase inhibitors in the prevention of urologic conditions.

Hernandez J, Basler JW, Thompson IM. Hernandez J, et al. Among authors: thompson im. Urol Clin North Am. 2004 May;31(2):213-8. doi: 10.1016/j.ucl.2004.01.009. Urol Clin North Am. 2004. PMID: 15123401 Review.

10

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.

Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, Parnes HL, Minasian LM, Ford LG, Lippman SM, Crawford ED, Crowley JJ, Coltman CA Jr. Thompson IM, et al. N Engl J Med. 2004 May 27;350(22):2239-46. doi: 10.1056/NEJMoa031918. N Engl J Med. 2004. PMID: 15163773 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

854 results

Search Page

Filters